[MO5] Mini-Oral Session 5　Hepatobiliary / Pancreatic Cancer 2（HCC, Pancreatic Cancer）
【E】

[MO5-1] Regorafenib in advanced HCC patients who were not included in the RESORCE trial: first interim analysis

^○Keisuke Koroki¹, Sadahisa Ogasawara^1,2, Iwanaga Terunao¹, Hidemi Unozawa¹, Kisako Fujiwara¹, Miyuki Nakagawa¹, Takafumi Sakuma¹, Naoto Fujita¹, Hiroaki Kanzaki¹, Kazufumi Kobayashi^1,2, Soichiro Kiyono¹, Masato Nakamura¹, Naoya Kanogawa¹, Tomoko Saito¹, Takayuki Kondo¹, Ryo Nakagawa¹, Shingo Nakamoto¹, Ryosuke Muroyama¹, Tetsuhiro Chiba¹, Naoya Kato¹ (1.Department of Gastroenterology, Graduate School of Medicine, Chiba University, 2.Translational Research and Development Center, Chiba University Hospital)